J. Goldman & Co LP Acquires New Position in Zenas BioPharma, Inc. $ZBIO

J. Goldman & Co LP acquired a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the second quarter, HoldingsChannel reports. The institutional investor acquired 68,232 shares of the company’s stock, valued at approximately $1,732,000.

Several other large investors have also added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in shares of Zenas BioPharma in the second quarter worth $508,000. The Manufacturers Life Insurance Company bought a new position in Zenas BioPharma in the 2nd quarter worth $204,000. Quantbot Technologies LP bought a new stake in Zenas BioPharma during the 2nd quarter valued at approximately $49,000. DCF Advisers LLC purchased a new stake in Zenas BioPharma during the 2nd quarter valued at approximately $715,000. Finally, BlackRock Inc. bought a new stake in Zenas BioPharma in the 2nd quarter valued at $68,176,000.

Zenas BioPharma Stock Up 6.7%

Zenas BioPharma stock opened at $33.77 on Wednesday. The business’s 50-day moving average price is $28.84 and its 200 day moving average price is $24.00. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -3.76 and a beta of -1.03. Zenas BioPharma, Inc. has a 52 week low of $13.50 and a 52 week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. As a group, sell-side analysts anticipate that Zenas BioPharma, Inc. will post -5.81 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Guggenheim reissued a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research note on Friday, August 14th. Morgan Stanley boosted their price objective on Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Finally, Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma presently has an average rating of “Moderate Buy” and a consensus price target of $45.71.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.